Alemtuzumab treatment for multiple sclerosis in Austria: An observational long-term outcome study.
Tobias MoserFabian FoettingerWolfgang HitzlBianka NovotnaThomas BergerGabriel BstehFranziska Di PauliHarald HegenBarbara KornekDieter LangenscheidtJohann SellnerPublished in: Annals of clinical and translational neurology (2024)
ALEM had long-lasting beneficial effects on the ARR and disability improvement, especially when initiated early in the course of the disease. Only a subset of patients received subsequent DMTs.